Turn Biotechnologies Acquires ARMM Technology for Enhanced Epigenetic Therapies
Deal News | Mar 26, 2025 | PR Newswire Cision Turn Biotechnologies, Inc.
Turn Biotechnologies has announced its strategic acquisition of ARMM (ARRDC1 Mediated Microvesicles) technology, licensed from Harvard University and all associated assets from Vesigen Therapeutics. This technology enhances Turn Biotechnologies’ capabilities in delivering a wide range of gene-editing proteins and RNA therapies through its eTurna™ LNP platform. The acquisition allows for precise and scalable epigenetic reprogramming in a variety of tissues, providing cutting-edge approaches in ophthalmology, dermatology, and immunology. Preclinical data demonstrate the effectiveness of ARMM in various tissues, suggesting a promising future in treating aging-related conditions and diseases. The acquisition has attracted interest from major investors like Bayer Healthcare, Morningside Group, and Alexandria Ventures, showcasing the potential impact of Turn Biotechnologies' advancements on the future of regenerative medicine.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – Turn Biotechnologies is based in Mountain View, California, and the technology was licensed from Harvard University in Cambridge, Massachusetts.
Industry
- Biotechnology – The article discusses advances in gene therapy and epigenetic reprogramming technologies, which are central themes in the biotechnology industry.
- Pharmaceuticals – The focus on developing therapies for age-related diseases and conditions aligns with the pharmaceutical industry's interest in innovative drug delivery systems.
- Healthcare – Turn Biotechnologies' acquisition of ARMM technology aims at revolutionizing treatments for diseases and conditions linked with aging, a major concern within the healthcare sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Turn Biotechnologies | Acquiring Company | Company | A biotech firm specializing in epigenetic reprogramming therapies for age-related diseases. |
| Harvard University | Licensor | Educational Institution | The origin of the ARMM technology, which was licensed to Turn Biotechnologies. |
| Vesigen Therapeutics | Technology Provider | Company | Developed the ARMM technology under a license from Harvard University. |
| Bayer Healthcare LLC | Investor | Company | A major global provider interested in Turn Biotechnologies' new capabilities. |
| Morningside Group Ltd. | Investor | Company | An investment group supporting Turn Biotechnologies' advancements. |
| Alexandria Ventures | Investor | Company | A venture capital firm investing in Turn Biotechnologies. |
| Anja Krammer | CEO | Person | Chief Executive Officer of Turn Biotechnologies. |